Mylan Telmisartan Amlodipine Recall: Quality-Control Lessons for the Generics Industry
What the Mylan telmisartan amlodipine recall shows about generic drug quality control, cross-border supply and how recalls are classified.
Mylan Telmisartan Amlodipine Recall: Quality-Control Lessons for the Generics Industry
What the Mylan telmisartan amlodipine recall shows about generic drug quality control, cross-border supply and how recalls are classified.
SCHOTT Pharma India Name Change: What It Signals for India Pharma Packaging
What the SCHOTT Pharma India name change signals for pharma packaging in India, with market data and a list of what remains undisclosed.
Indoco Remedies AnaCipher ANVISA Approval: What It Means for India CROs
The Indoco Remedies AnaCipher ANVISA approval adds Brazil to a growing CRO’s reach. Industry data, the business logic and what is undisclosed.
B. Braun Bloodline Alert: What Dialysis Providers Should Check
What the B. Braun Streamline Bloodline Set FDA alert means for dialysis providers and buyers: lots, steps B. Braun asked for, and open questions.
Novartis Q3 2026 Results: Why Reported Profit Fell While Core Earnings Rose
Reading the Novartis Q3 2026 results: why reported profit fell 70% while core profit rose, and what the raised guidance means.
Indira IVF Sabine Acquisition: What the Reported Deal Means for Investors
What the Indira IVF Sabine acquisition could mean for investors: reported terms, implied valuation, IPO context and what remains undisclosed.
AstraZeneca Stomach Cancer Drug Trial: Sone-Ve Versus the Rival Claudin 18.2 ADC
How the AstraZeneca stomach cancer drug trial compares with Takeda’s rival claudin 18.2 ADC, plus regulatory status and corrected numbers.
Takeda Gastric Cancer Drug Trial: Filing Plans, Partner and Pipeline Impact
After the Takeda gastric cancer drug trial: planned Japan filing, China priority review, the Innovent partnership and what is still unknown.
Roche Divarasib Phase 3 Trial: What It Means for Lumakras and Krazati
The Roche divarasib Phase 3 trial beat sotorasib and adagrasib on survival. What it means for competitors, analysts and the untreated-patient market.
